



## PRIOR AUTHORIZATION POLICY

**POLICY:** Oncology – Pemazyre Prior Authorization Policy

- Pemazyre® (pemigatinib tablets – Incyte)

**REVIEW DATE:** 05/10/2023

### **INSTRUCTIONS FOR USE**

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

## **CIGNA NATIONAL FORMULARY COVERAGE:**

### **OVERVIEW**

Pemazyre, a kinase inhibitor, is indicated in adults for the following uses:<sup>1</sup>

- Previously treated, unresectable locally advanced or metastatic **cholangiocarcinoma** with a fibroblast growth factor receptor 2 (*FGFR2*) fusion or other rearrangement as detected by an FDA-approved test.
- Relapsed or refractory **myeloid/lymphoid neoplasms** with fibroblast growth factor receptor 1 (*FGFR1*) rearrangement.

### **Guidelines**

Pemazyre is addressed in National Comprehensive Cancer Network (NCCN) guidelines:<sup>2</sup>

- **Biliary tract cancers:** Guidelines (version 1.2023 – March 10, 2023) recommend Pemazyre for disease progression on or following systemic treatment for patients with unresectable or metastatic cholangiocarcinoma with *FGFR2* fusion or rearrangement, as a single agent (category 2A).<sup>3</sup>
- **Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Fusion Genes:** Guidelines (version 2.2022 – October 18, 2022) recommend Pemazyre for the treatment of myeloid/lymphoid neoplasms with eosinophilia and *FGFR1* rearrangement in chronic phase or blast phase (category 2A).<sup>2,4</sup>

## **POLICY STATEMENT**

Prior Authorization is recommended for prescription benefit coverage of Pemazyre. All approvals are provided for the duration noted below.

- **Pemazyre® (pemigatinib tablets ( Incyte)) is(are) covered as medically necessary when the following criteria is(are) met for FDA-approved indication(s) or other uses with supportive evidence (if applicable):**

### **FDA-Approved Indications**

**1. Cholangiocarcinoma.** Approve for 1 year if the patient meets ALL of the following criteria (A, B, C, and D):

**A)** Patient is  $\geq$  18 years of age; AND

**B)** Patient has unresectable locally advanced or metastatic disease; AND

**C)** Tumor has fibroblast growth factor receptor 2 (*FGFR2*) fusion or other rearrangement, as detected by an approved test; AND

**D)** Patient has been previously treated with at least one systemic regimen.

Note: Examples of systemic regimens are gemcitabine + cisplatin, 5-fluorouracil + oxaliplatin or cisplatin, capecitabine + cisplatin or oxaliplatin, gemcitabine + Abraxane (albumin-bound paclitaxel) or capecitabine or oxaliplatin, gemcitabine + Abraxane + cisplatin, FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin), FOLFIRI (5-fluorouracil, leucovorin, irinotecan), Stivarga (regorafenib tablets).

**2. Myeloid/Lymphoid Neoplasms.** Approve for 1 year if the patient meets ALL of the following criteria (A, B, C, and D):

**A)** Patient is  $\geq$  18 years of age; AND

**B)** Patient has eosinophilia; AND

**C)** The cancer has fibroblast growth factor receptor 1 (*FGFR1*) rearrangement, as detected by an approved test; AND

**D)** The cancer is in chronic phase or blast phase.

### **CONDITIONS NOT COVERED**

- **Pemazyre® (pemigatinib tablets ( Incyte)) is(are) considered experimental, investigational or unproven for ANY other use(s).**

### **REFERENCES**

1. Pemazyre® tablets [prescribing information]. Wilmington, DE: Incyte; August 2022.
2. The NCCN Drugs & Biologics Compendium. © 2023 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on May 4, 2023. Search term: pemigatinib.

3. The NCCN Biliary Tract Cancers Clinical Practice Guidelines in Oncology (version 1.2023 – March 10, 2023). © 2023 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on May 5, 2023.
4. The NCCN Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Fusion Genes Clinical Practice Guidelines in Oncology (version 2.2022 – October 18, 2022). © 2022 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on May 4, 2023.

## HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	<b>Cholangiocarcinoma.</b> Added requirement that the patient is $\geq 18$ years of age. <b>Myeloid/Lymphoid Neoplasms.</b> Added new condition of approval.	05/04/2022
Selected Revision	<b>Cholangiocarcinoma.</b> Changed approval duration from 3 years to 1 year. <b>Myeloid/Lymphoid Neoplasms.</b> Changed approval duration from 3 years to 1 year.	06/22/2022
Selected Revision	<b>Myeloid/Lymphoid Neoplasms:</b> Moved indication to FDA-Approved Indications.	09/14/2022
Annual Revision	No criteria changes.	05/10/2023

"Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation.  
 © 2023 Cigna